Otenzepad

• CAT Number: I010369
• CAS Number: 102394-31-0
• Molecular Formula: C24H31N5O2
• Molecular Weight: 421.54
• Purity: ≥95%
• Synonyms: 11-[2-[2-(diethylaminomethyl)piperidin-1-yl]acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one
• InChI: InChI=1S/C24H31N5O2/c1-3-27(4-2)16-18-10-7-8-15-28(18)17-22(30)29-21-13-6-5-11-19(21)24(31)26-20-12-9-14-25-23(20)29/h5-6,9,11-14,18H,3-4,7-8,10,15-17H2,1-2H3,(H,26,31)
• InChIKey: UBRKDAVQCKZSPO-UHFFFAOYSA-N
• SMILES: CCN(CC)CC1CCCCN1CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4

Otenzepad (Cat No.: I010369) is a selective muscarinic M2 receptor antagonist developed for the treatment of bradycardia and other cardiovascular conditions. By blocking M2 receptors, which are primarily found in the heart, otenzepad reduces parasympathetic nervous system activity, thereby increasing heart rate and improving cardiac output. It was also explored for potential use in treating gastrointestinal and urinary disorders. Although it showed promise in early clinical trials, otenzepad has not been widely adopted in clinical practice. Side effects may include dry mouth, blurred vision, and tachycardia.

Reference

[1]. Bloom JW, et al. Heterogeneity of the M1 muscarinic receptor subtype between peripheral lung and cerebral cortex demonstrated by the selective antagonist AF-DX 116. Life Sci. 1987 Jul 27;41(4):491-6.
[Content Brief]

[2]. Packard MG, et al. Post-training injection of the acetylcholine M2 receptor antagonist AF-DX 116 improves memory. Brain Res. 1990 Jul 30;524(1):72-6.
[Content Brief]

[3]. Kopf SR, et al. AF-DX 116, a presynaptic muscarinic receptor antagonist, potentiates the effects of glucose and reverses the effects of insulin on memory. Neurobiol Learn Mem. 1998 Nov;70(3):305-13.
[Content Brief]